Just What the Doctor Ordered for the Ailing Portfolio
A quick glance at some of the major pharmaceutical companies will show that many of their stocks have tanked recently. Concerns about safety issues, and the fear that the Food and Drug Administration may not be doing its job, have set off a wave of selling that is apt to continue for some time.
But a closer look at the industry as a whole, and the hardest-hit companies in particular, shows great potential for the medium- to long-term investor.1
There are a number of trends that point to one inescapable c.....